Summary
The design of enzymatic catalysts and protein therapeutics with tailored, new-to-nature properties is a long-standing goal in enzymology and cell biology. Nature generally uses 20 amino acids as building blocks for protein synthesis. However, this portfolio limits the options for engineering proteins with ‘un-natural’ activities. Recent developments in the expansion of the genetic code have the potential to revolutionise the design of novel enzymes; by reprogramming the genetic code, we could convey novel functionality into proteins and extend their properties. This project aims at incorporating thiazolium amino acids into the active site of a promiscuous and highly evolvable de novo enzyme, namely the RA95 (retro)-aldolase, for orchestrating organocatalytic transformations of clinical and industrial interest. Such reactions, conventionally mediated by non-enzymatic, small molecule N-heterocyclic carbene (NHC) catalysts require high temperature and catalyst loading. An engineered enzyme with the ability to catalyse such chemistry may overcome the drawbacks of these abiological catalysts, serving as a ‘greener’ biocatalytic alternative, and also perform the desired reactions in cells for medicinal purposes. This initiative will pave the way for development of general strategies for creating enzymes with unique properties and provide a tool-box for efficient, environmentally-friendly and bioorthogonal organocatalysed reactions. It is anticipated that the generated artificial biocatalysts will have attractive applications in research, medicine and industry.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/846170 |
| Start date: | 15-09-2019 |
| End date: | 14-09-2021 |
| Total budget - Public funding: | 191 149,44 Euro - 191 149,00 Euro |
Cordis data
Original description
The design of enzymatic catalysts and protein therapeutics with tailored, new-to-nature properties is a long-standing goal in enzymology and cell biology. Nature generally uses 20 amino acids as building blocks for protein synthesis. However, this portfolio limits the options for engineering proteins with ‘un-natural’ activities. Recent developments in the expansion of the genetic code have the potential to revolutionise the design of novel enzymes; by reprogramming the genetic code, we could convey novel functionality into proteins and extend their properties. This project aims at incorporating thiazolium amino acids into the active site of a promiscuous and highly evolvable de novo enzyme, namely the RA95 (retro)-aldolase, for orchestrating organocatalytic transformations of clinical and industrial interest. Such reactions, conventionally mediated by non-enzymatic, small molecule N-heterocyclic carbene (NHC) catalysts require high temperature and catalyst loading. An engineered enzyme with the ability to catalyse such chemistry may overcome the drawbacks of these abiological catalysts, serving as a ‘greener’ biocatalytic alternative, and also perform the desired reactions in cells for medicinal purposes. This initiative will pave the way for development of general strategies for creating enzymes with unique properties and provide a tool-box for efficient, environmentally-friendly and bioorthogonal organocatalysed reactions. It is anticipated that the generated artificial biocatalysts will have attractive applications in research, medicine and industry.Status
CLOSEDCall topic
MSCA-IF-2018Update Date
28-04-2024
Images
No images available.
Geographical location(s)
